<DOC>
	<DOCNO>NCT00500539</DOCNO>
	<brief_summary>The primary objective study ass immunogenic potential liquid formulation omalizumab administer period 6 month moderate severe persistent allergic asthma patient 12 year age old , previous exposure drug ( omalizumab na√Øve patient ) . The secondary objective study assess safety liquid formulation omalizumab patient .</brief_summary>
	<brief_title>Open Label Study Assess Safety Immunogenicity Omalizumab Liquid Formulation .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients 12 year old moderate severe allergic asthma Body weight great 30kg less 150 kg total serum IgE level great 30 less 700 IU/ml Diagnosis allergic asthma great 1 year duration , accord American Thoracic Society criterion ( 14 ) screening , history consistent clinical feature moderate severe persistent asthma . Positive skin prick test ( diameter wheel great 3mm ) least one perennial allergen within previous one year visit 1 , patient expose regular basis ( day ) duration study . No clinically significant asthma exacerbation require treatment systemic corticosteroid four week immediately prior screen visit ( Visit 1 ) screening period ( Visit 1 2 ) Demonstrated evidence inadequate asthma symptom control , despite treatment ICS accord clinical feature moderate severe persistent asthma . Previous exposure omalizumab Previous exposure humanize protein monoclonal antibody Known HAHA monoclonal antibody History hypersensitivity study drug drug similar chemical structure Known hypersensitivity ingredient , include excipients study medication drug relate omalizumab ( e.g . monoclonal antibody , polyclonal gamma globulin ) Active lung disease allergic asthma ( e.g . cystic fibrosis , bronchiectasis ) Elevated serum IgE level reason allergy ( e.g . parasite infection , hyperimmunoglobulin E syndrome , WiskottAldrich Syndrome allergic bronchopulmonary aspergillosis )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>omalizumab</keyword>
	<keyword>safety</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>adolescent</keyword>
</DOC>